clopidogrel has been researched along with everolimus in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.41) | 29.6817 |
| 2010's | 30 (81.08) | 24.3611 |
| 2020's | 5 (13.51) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Akishita, M; Ako, J; Eto, M; Iijima, K; Ogawa, S; Ota, H; Ouchi, Y | 1 |
| Doganov, A; Formuszewicz, R; Gil, RJ; Rusicka-Piekarz, T; Vassilev, D | 1 |
| Abele-Ohl, S; Eckl, S; Ensminger, SM; Heim, C; Hoffmann, J; Ramsperger-Gleixner, M; Weyand, M | 1 |
| Caixeta, A; Gordon, P; Hermiller, JB; Jonnavithula, L; Lansky, AJ; Miquel-Hebert, K; Onuma, Y; Ruygrok, P; Serruys, PW; Sood, P; Stone, GW; Su, X; Sudhir, K; Veldhof, S; Yaqub, M | 1 |
| Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Devlin, G; Hyde, L; Liang, M; Liew, TV; Puri, A | 1 |
| Ferraro, G; Gaita, F; Marcolongo, M; Moretti, C; Sheiban, I; Truffa, A | 1 |
| Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Huang, KN | 1 |
| Eckl, S; Ensminger, SM; Koch, N; Preidl, RH; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M | 1 |
| Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Marchesini, J; Minarelli, M; Parrinello, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Eckl, S; Ensminger, SM; Goldmann, K; Heim, C; Koch, N; Preidl, R; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M | 1 |
| Chen, F; Loh, JP; Omar, A; Pendyala, LK; Pichard, AD; Satler, LF; Torguson, R; Waksman, R | 1 |
| Alfonso Manterola, F; Doncel Vecino, LJ; Fernández Díaz, JA; Fernández Portales, J; González Fernández, R; López Mínguez, JR; Martínez Cáceres, G; Martínez Romero, P; Merchán Herrera, A; Nogales Asensio, JM; Romany, S; Sandoval, J | 1 |
| Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Hirata, K; Iwasaki, M; Kinutani, H; Konishi, A; Masaru, K; Nakagawa, M; Nishio, R; Osue, T; Otake, H; Sawada, T; Shinke, T; Shite, J; Takahashi, H; Takaya, T; Taniguchi, Y; Terashita, D | 1 |
| Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW | 1 |
| Jim, MH; Wong, KL; Yiu, KH | 1 |
| Guo, XF; Han, YL; Li, B; Liu, Q; Lu, SZ; Pang, S; Su, X; Xu, B; Yang, YJ; Zhang, YJ; Zhao, YL | 1 |
| Akasaka, T; Hanawa, K; Hao, K; Hasebe, Y; Hirano, M; Ito, K; Matsumoto, Y; Miyata, S; Nishimiya, K; Ogata, T; Oyama, K; Shimokawa, H; Shindo, T; Takahashi, J; Tanaka, A; Taruya, A; Tsuburaya, R; Uzuka, H | 1 |
| Caixeta, A; Généreux, P; Hermiller, JB; Jones-McMeans, J; Kedhi, E; Krucoff, MW; Palmerini, T; Rutledge, DR; Serruys, PW; Simonton, CA; Stone, GW; Sudhir, K; Wang, J | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ito, M; Izumi, D; Miyahara, M; Sakai, M | 1 |
| Ensminger, SM; Heim, C; Koch, N; Motsch, B; Ramsperger-Gleixner, M; Weyand, M | 1 |
| Kesavamoorthy, B; Virmani, R; Yahagi, K | 1 |
| Chang, K; Choi, YS; Chung, WB; Chung, WS; Kim, HY; Kim, JY; Kwon, A; Lee, MY; Park, CS; Seung, KB | 1 |
| Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH | 1 |
| Cho, DK; Choi, JH; Choi, SH; Doh, JH; Gwon, HC; Hahn, JY; Kim, SH; Lee, JB; Lee, JM; Lee, SH; Oh, JH; Park, TK; Song, YB; Yang, JH | 1 |
| Açıl, T; Doğan, A; Kahraman, S; Kurtoğlu, N; Özdemir, E; Saltan, Y | 1 |
| Akasaka, T; Hariki, H; Hiranuma, N; Hirata, KI; Inoue, T; Iwasaki, M; Kinutani, H; Konishi, A; Kuroda, M; Nakagawa, M; Nakamura, M; Nishio, R; Osue, T; Otake, H; Saito, S; Shinke, T; Shite, J; Taniguchi, Y | 1 |
| Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T | 1 |
| Abe, M; Ando, K; Igarashi Hanaoka, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakao, K; Natsuaki, M; Tanabe, K; Watanabe, H | 1 |
| Yokoyama, H | 1 |
| Haruta, H; Hirayama, A; Hiro, T; Kitano, D; Kurosawa, T; Li, Y; Matsumoto, T; Migita, S; Mitsumata, M; Okumura, Y; Sudo, M; Takahashi, R; Takayama, T; Taniguchi, Y | 1 |
| Ensminger, SM; Heim, C; Kuckhahn, A; Nicolls, MR; Ramsperger-Gleixner, M; Weyand, M | 1 |
| Ando, K; Domei, T; Fujii, S; Hayashi, F; Isawa, T; Ishii, M; Kimura, T; Komiyama, K; Mori, H; Morimoto, T; Natsuaki, M; Nikaido, A; Nishikura, T; Obayashi, Y; Ogita, M; Ohya, M; Shigematsu, T; Suematsu, N; Suwa, S; Suzuki, H; Tada, T; Tatsushima, S; Watanabe, H; Watanabe, N; Yamaji, K; Yamamoto, K | 1 |
2 review(s) available for clopidogrel and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
Topics: Aspirin; Cardiotonic Agents; Clopidogrel; Drug-Eluting Stents; Everolimus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Time Factors | 2013 |
11 trial(s) available for clopidogrel and everolimus
| Article | Year |
|---|---|
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Graft Occlusion, Vascular; Humans; Hyperplasia; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Sirolimus; Stents; Stroke; Ticlopidine; Tunica Intima | 2013 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Hyperplasia; Italy; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Myocardial Infarction; Neointima; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Factors; Sirolimus; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Treatment Outcome; Tubulin Modulators | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Early Termination of Clinical Trials; Europe; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Time Factors; Withholding Treatment | 2015 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Intention to Treat Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Lower on-treatment platelet reactivity during everolimus-eluting stent implantation contributes to the resolution of post-procedural intra-stent thrombus: serial OCT observation in the PRASFIT-Elective study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Everolimus; Female; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Treatment Outcome | 2020 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
24 other study(ies) available for clopidogrel and everolimus
| Article | Year |
|---|---|
Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
Topics: Aspirin; Cellular Senescence; Cilostazol; Clopidogrel; Down-Regulation; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Humans; Immunosuppressive Agents; Nitric Oxide Synthase Type III; Oxidative Stress; Paclitaxel; Plasminogen Activator Inhibitor 1; Platelet Aggregation Inhibitors; Sirolimus; Sirtuin 1; Sirtuins; Tetrazoles; Ticlopidine; Vasodilator Agents | 2009 |
The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Image Interpretation, Computer-Assisted; Immunosuppressive Agents; Male; Mathematics; Multivariate Analysis; Odds Ratio; Paclitaxel; Platelet Aggregation Inhibitors; Poland; Registries; Retrospective Studies; Sirolimus; Statistics as Topic; Ticlopidine; Time Factors | 2009 |
Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Everolimus; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Platelet Aggregation; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine; Transplantation, Homologous; Treatment Outcome | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Risk Reduction Behavior; Sirolimus; Ticlopidine; Time Factors | 2010 |
Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; New Zealand; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Sirolimus; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
When coronary angiography is not enough to detect spontaneous left main coronary artery dissection.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Metoprolol; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Smoking; Ticlopidine; Treatment Outcome | 2012 |
Clopidogrel reduces post-transplant obliterative bronchiolitis.
Topics: Animals; Blood Platelets; Bronchiolitis Obliterans; Calcineurin Inhibitors; Clopidogrel; Cytokines; Everolimus; Gene Expression Regulation; Immunohistochemistry; Isoantibodies; Lung Diseases; Lung Transplantation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Microscopy, Fluorescence; Models, Animal; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; T-Lymphocytes; Tacrolimus; Ticlopidine; Time Factors; TOR Serine-Threonine Kinases; Trachea | 2013 |
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts.
Topics: Allografts; Animals; Aorta; Arteriosclerosis; Clopidogrel; Disease Progression; Everolimus; Immunity, Humoral; Isoantibodies; Mice; Mice, Inbred C57BL; Sirolimus; Ticlopidine | 2015 |
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Angiography; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Graft Occlusion, Vascular; Hospital Mortality; Humans; Male; Middle Aged; Paclitaxel; Prosthesis Failure; Registries; Retrospective Studies; Severity of Illness Index; Sirolimus; Survival Analysis; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Withholding Treatment | 2014 |
Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation.
Topics: Aged; Clopidogrel; Coronary Angiography; Cytochrome P-450 Enzyme System; Drug-Eluting Stents; Everolimus; Female; Genotype; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2015 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Drug-Eluting Stents; Everolimus; Female; Graft Occlusion, Vascular; Humans; Male; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Reoperation; Saphenous Vein; Ticlopidine | 2015 |
Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Thrombosis; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Disease Progression; Drug-Eluting Stents; Everolimus; Female; Humans; Interferometry; Male; Middle Aged; Neointima; Neovascularization, Physiologic; Platelet Aggregation Inhibitors; Postoperative Period; Prosthesis Implantation; Sirolimus; Stents; Swine; Swine, Miniature; Ticlopidine; Tomography, Optical Coherence; Vasa Vasorum; Vasculitis | 2015 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2016 |
Microvascular integrity plays an important role for graft survival after experimental skin transplantation.
Topics: Allografts; Animals; Clopidogrel; Drug Therapy, Combination; Everolimus; Graft Rejection; Graft Survival; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Microvessels; Neovascularization, Physiologic; Platelet Aggregation Inhibitors; Skin Transplantation; Ticlopidine | 2015 |
Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy.
Topics: Absorbable Implants; Adult; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Prosthesis Design; ST Elevation Myocardial Infarction; Ticlopidine; Tissue Scaffolds; Withholding Treatment | 2017 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Registries; Sirolimus; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
Impact of early (3 months) dual antiplatelet treatment interruption prior to renal transplantation in patients with second-generation DES on perioperative stent thrombosis and MACEs.
Topics: Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Everolimus; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Period; Retrospective Studies; Sirolimus; Thrombosis | 2017 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Proportional Hazards Models; Randomized Controlled Trials as Topic; Single-Blind Method; Stroke | 2019 |
What Is the Optimal Dual Antiplatelet Therapy Strategy After Percutaneous Coronary Intervention in the Era of New-Generation Drug-Eluting Stent?
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Family Characteristics; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents | 2020 |
Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model.
Topics: Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Factor Xa Inhibitors; Graft Occlusion, Vascular; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Swine; Tomography, Optical Coherence | 2022 |
Microvasculature in murine tracheal allografts after combined therapy with clopidogrel and everolimus.
Topics: Allografts; Animals; Bronchiolitis Obliterans; Clopidogrel; Everolimus; Graft Rejection; Lung Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred CBA; Microvessels; Trachea | 2021 |